Quest Diagnostics (DGX) vs Humana (HUM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Humana (HUM) has outperformed Quest Diagnostics (DGX) over the past year, gaining 71.7% versus a gain of 35.0%. Over five years, DGX leads with a +66.7% price change compared with -9.0% for HUM. Humana is the larger company by market cap ($46.84 billion vs $28.42 billion), about 1.6 times the size, while Quest Diagnostics is growing revenue faster (+11.8% vs +10.1%).
On valuation, Humana trades at a lower forward P/E (21.1x vs 21.6x for Quest Diagnostics). Quest Diagnostics offers the higher dividend yield (1.31% vs 0.91%). Quest Diagnostics converts more of its revenue into profit, with a net margin of 9.0% versus 0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DGX | HUM |
|---|---|---|
| Share price | $258.28 | $390.00 |
| Market cap | $28.42B | $46.84B |
| 1-day change | -0.31% | +2.63% |
| YTD return | +48.84% | +52.27% |
| 1-year return | +35.05% | +71.73% |
| 5-year return | +66.69% | -8.98% |
| P/E ratio (TTM) | 25.73 | 38.05 |
| Forward P/E | 21.55 | 21.06 |
| EPS (TTM) | $10.04 | $10.25 |
| Dividend yield | 1.31% | 0.91% |
| Annual dividend | $3.38 | $3.54 |
| Revenue (latest FY) | $11.04B | $129.66B |
| Revenue growth (YoY) | +11.78% | +10.11% |
| Net income (latest FY) | $992.00M | $1.19B |
| Gross margin | 33.21% | — |
| Operating margin | 14.10% | 2.09% |
| Net margin | 8.99% | 0.92% |
| 52-week high | $263.19 | $462.87 |
| 52-week low | $171.18 | $163.11 |
| Distance from 52-week high | -1.87% | -15.74% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -0.39% | +30.98% |
| Average volume | 1.03M | 1.46M |
| Shares outstanding | 110.02M | 120.10M |
| Employees | 60,000 | 67,060 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUM has outperformed DGX by 36.7 percentage points over the past year.
- Humana trades at a higher earnings multiple (38.0x vs 25.7x trailing P/E).
- Quest Diagnostics is more profitable, keeping 9.0 cents of every revenue dollar as net income versus 0.9 cents for Humana.
About Quest Diagnostics
DGX stock →Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Health Care · Medical Specialities · 60,000 employees
About Humana
HUM stock →Humana Inc. provides medical and specialty insurance products in the United States.
Health Care · Medical Specialities · 67,060 employees
DGX vs HUM FAQ
Which is bigger, Quest Diagnostics or Humana?
Humana (HUM) is larger, with a market capitalization of $46.84B compared with $28.42B for Quest Diagnostics (DGX).
Which stock has performed better over the past year, DGX or HUM?
HUM returned +71.73% over the past 12 months, compared with +35.05% for DGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DGX or HUM?
DGX has the lower trailing P/E at 25.7, versus 38.0 for HUM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Quest Diagnostics or Humana?
Quest Diagnostics has the higher yield at 1.31%, compared with 0.91% for Humana.
Are Quest Diagnostics and Humana in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.